 The really nice thing is I feel like we're getting into an area where you'll get a bifurcation. If you present with cancer, you do NGS, you do genomic sequencing, I should say. If you have one or two mutations, then hopefully we will have developed a precision med that can go after the thing that's causing the cancer, block it, get a great outcome for the patient. If you have a lot of mutations, hey, immunoconcology works well for you then, because if you have a lot of mutations, the cancer doesn't look like self, and your immune system will react to it. So that is the bifurcation I want. Now I hope we can get to a point where the only reason you need chemo or cytotoxic agents is to shrink the margins before surgery. That is not going to be the standard of care five or ten years from now. It's just going to be precision med and immunoconcology. That's what we're driving for.